Примери за използване на Closely monitored for signs на Английски и техните преводи на Български
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Patients should be closely monitored for signs and symptoms of pancreatitis.
Patients who are concurrently treated with busulfan and itraconazole ormetronidazole should be closely monitored for signs of busulfan toxicity.
Patients should be closely monitored for signs or symptoms of these events.
If PNH patients discontinue treatment with Soliris they should be closely monitored for signs and symptoms of serious intravascular haemolysis.
Patients should be closely monitored for signs of IMBRUVICA toxicity if a CYP3A4 inhibitor must be used(see sections 4.2 and 4.5).
If patients are re-treated after a prolonged period,they must be closely monitored for signs and symptoms of delayed hypersensitivity.
Patients should be closely monitored for signs and symptoms that are suggestive of acute pancreatitis.
Patients taking concomitant medications with disposition dependent upon P-gp and with narrow therapeutic index(e.g. digoxin, dabigatran, aliskiren)should be closely monitored for signs of changed tolerability as a result of increased exposure of the concomitant medication whilst receiving TAGRISSO(see section 5.2).
Patients should be closely monitored for signs of cardiovascular adverse reactions throughout treatment.
Patients with influenza should be closely monitored for signs of abnormal behaviour.
Patients should be closely monitored for signs and symptoms of excessive exposure to the medicinal products and reduction of the dose of these medicinal products should be considered.
Trade data from China on Thursday will be closely monitored for signs of an impact on the economy.
Patients should be closely monitored for signs or symptoms of TLS, including renal function and fluid balance in the first 48 hours after the first infusion.
Patients taking concomitant medications with disposition dependent upon BCRP andwith narrow therapeutic index should be closely monitored for signs of changed tolerability of the concomitant medication as a result of increased exposure whilst receiving TAGRISSO(see section 5.2).
Patients should be closely monitored for signs of hypersensitivity during and for at least 30 minutes after each administration of an intravenous iron product.
However, such patients should be closely monitored for signs and symptoms of cerebral bleeding.
Patients should be closely monitored for signs and symptoms of excessive exposure to the medicinal products and reduction of the dose of these medicinal products should be considered.
Patients with these characteristics should be closely monitored for signs and symptoms of hepatic decompensation.
Patients should be closely monitored for signs and symptoms of respiratory depression and sedation(see section 4.5).
In case of overdose,patients should be closely monitored for signs or symptoms of adverse reactions.
In the event of an overdose, patients must be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic and supportive treatment initiated, taking into consideration the long half-life estimated at 113 hours.
Patients with these characteristics should be closely monitored for signs and symptoms of hepatic decompensation(see section 4.4).
Patients should be closely monitored for signs related to venetoclax toxicities.
These patients should be closely monitored for signs and symptoms of active HBV infection throughout therapy.
In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions and supportive treatment initiated.
Patients at risk of B1 deficiency should be closely monitored for signs and symptoms of encephalopathy after arsenic trioxide initiation.
In case of overdose, patients must be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted.
In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment instituted immediately.
In the event of overdose, patients must be closely monitored for signs or symptoms of adverse reactions and appropriate symptomatic treatment and supportive measures instituted.
Carriers of HBV who require treatment with Hulio should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy.